Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial


ÖZKAN M., GÜNDÜZ S., GÜRSOY O. M. , KARAKOYUN S., ASTARCIOĞLU M. A. , KALÇIK M., ...More

AMERICAN HEART JOURNAL, vol.170, no.2, pp.409-419, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 170 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.1016/j.ahj.2015.04.025
  • Journal Name: AMERICAN HEART JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.409-419
  • Kütahya Health Sciences University Affiliated: No

Abstract

Background Low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator (t-PA) with repetition as needed has been shown to provide effective and safer thrombolysis in patients with prosthetic valve thrombosis (PVT). Further prolonging the infusion time may be rational with regard to reducing complication rates without reducing success rates. We aimed to investigate the efficacy and safety of ultraslow (25 hours) infusion of low-dose (25 mg) alteplase (t-PA) for PVT.